Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00244595 | Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age | PHASE3 | COMPLETED | 235 | — | — | Sep 1, 2003 | Nov 1, 2006 | Dec 9, 2009 | 44 | United States, Belgium +2 |
| Name | Type | Description |
|---|---|---|
| candsartan cilexetil | DRUG | - |
Inclusion Criteria: * The subjects must have fulfilled the eligibility criteria for and have participated in Study 261A or did not participate in Study 261A but meet the following criteria: * Diagnosed and untreated hypertension, or * Diagnosed and treated, but off antihypertensive treatment for at...